4-乙基-5-硝基-2-吡啶胺 | 70936-17-3

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 4-乙基-5-硝基-2-吡啶胺
• 英文名称: 4-ethyl-5-nitropyridin-2-amine
• CAS: 70936-17-3
• 化学式: C₇H₉N₃O₂
• 分子量: 167.167
• InChiKey: CVDGEIBJXXVNDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-乙基-5-硝基-2-吡啶胺 在 镍 氢溴酸 、 氢气 、 溴 、 溶剂黄146 、 sodium nitrite 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 43.5h， 生成 5-溴-3-甲基-1H-吡唑并[3,4-c]吡啶
  参考文献：
  名称：

  Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt

  摘要：

  Thr-211 is one of three different amino acid residues in the kinase domain of protein kinase B/Akt as compared to protein kinase A (PKA), a closely related analog in the same AGC family. In an attempt to improve the potency and selectivity of our indazole-pyridine series of Akt inhibitors over PKA, efforts have focused on the incorporation of a chemical functionality to interact with the hydroxy group of Thr-211. Several substituents including an oxygen anion, amino, and nitro groups have been introduced at the C-6 position of the indazole scaffold, leading to a significant drop in Akt potency. Incorporation of a nitrogen atom into the phenyl ring at the same position (i.e., 9f) maintained the Akt activity and, in some cases, improved the selectivity over PKA. The structure-activity relationships of the new pyridine-pyrazolopyridine series of Akt inhibitors and their structural features when bound to PKA are also discussed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.01.010
• 作为产物：
  描述：

  4-乙基吡啶 在 硫酸 、 硝酸 、 sodium amide 、 paraffin 作用下， 生成 4-乙基-5-硝基-2-吡啶胺
  参考文献：
  名称：

  Catalytic Synthesis of Heterocycles.¹ X. Dehydrocyclization of 4-Ethyl-3-pyridinethiol to 6-Azathianaphthene

  摘要：

  DOI：

  10.1021/jo01106a028

文献信息

• [EN] PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLOPYRIDAZINE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：GOSSAMER BIOSERVICES INC

  公开号：WO2022109492A1

  公开（公告）日：2022-05-27

  Described herein are inhibitors of JAK kinases, pharmaceutical compositions comprising them, processes for preparing them and uses of such inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.

  本文描述了JAK激酶抑制剂，包括它们的制药组合物、制备它们的过程以及使用这些抑制剂来治疗或预防与激酶功能相关的疾病、紊乱和病况。